Novo Nordisk A/S
-
Health News
Weight loss drugs, Alzheimer’s treatments and gene editing: Enormous firsts defined 2023 in pharma
[ad_1] Soumyabrata Roy | Nurphoto | Getty Images Drugmakers are closing out a year when they achieved several historic firsts…
Read More » -
Business
The weight loss drug boom isn’t over yet — here’s what to expect in the year ahead
[ad_1] George Frey | Bloomberg | Getty Images Weight loss drugs exploded into the public eye this year, and 2024…
Read More » -
Health News
Prescriptions for Eli Lilly’s new weight-loss drug get off to a strong start and confirm bright outlook
[ad_1] The launch of Eli Lilly ‘s weight-loss drug Zepbound — a key pillar of our investment thesis in the…
Read More » -
Health News
If you can’t build the next Ozempic, buy it: Where M&A could be heading in the obesity drug space
[ad_1] Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk…
Read More » -
Health News
Weight gain after stopping Eli Lilly’s new obesity treatment should help, not hurt the stock
[ad_1] Some Eli Lilly investors appear concerned about clinical trial data that showed patients regained weight after they stopped taking…
Read More » -
Business
Patients regain weight after stopping Eli Lilly’s Zepbound, study says
[ad_1] Eli Lilly’s drug tirzepatide was approved for weight loss by the FDA. Courtesy of Eli Lilly Patients who took…
Read More » -
Business
Pfizer’s twice-daily weight loss pill joins a long list of obesity drug flops
[ad_1] Sopa Images | Lightrocket | Getty Images Pfizer’s twice-daily version of its experimental weight loss pill has now joined…
Read More » -
Health News
Why Pfizer’s latest stumble in the obesity market is a boon for Eli Lilly
[ad_1] Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news…
Read More » -
Business
Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
[ad_1] Pfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese…
Read More » -
Pics News
Novo Nordisk sues two pharmacies for allegedly selling tainted Wegovy, Ozempic knockoffs
[ad_1] A 0.25 mg injection pen of Novo Nordisk’s weight loss drug Wegovy is shown in this photo in Oslo,…
Read More »